1. Roehlen, N, Crouchet, E, Baumert, TF. Liver fibrosis: mechanistic concepts and therapeutic perspectives. Cells 2020; 9: 875.
Google Scholar | Crossref2. Kumar, S, Duan, Q, Wu, R, et al. Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis. Adv Drug Deliv Rev 2021; 176: 113869.
Google Scholar | Crossref | Medline3. Parola, M, Pinzani, M. Liver fibrosis: pathophysiology, pathogenetic targets and clinical issues. Mol Aspects Med 2019; 65: 37–55.
Google Scholar | Crossref | Medline4. Zhang, CY, Yuan, WG, He, P, et al. Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets. World J Gastroenterol 2016; 22: 10512–10522.
Google Scholar | Crossref | Medline5. Ozakyol, A . Global epidemiology of hepatocellular carcinoma (HCC epidemiology). J Gastrointest Cancer 2017; 48(3): 238–240.
Google Scholar | Crossref | Medline6. Asrani, SK, Devarbhavi, H, Eaton, J, et al. Burden of liver diseases in the world. J Hepatol 2019; 70: 151–171.
Google Scholar | Crossref | Medline7. Wu, DB, Chen, EQ, Tang, H. Stem cell transplantation for the treatment of end-stage liver disease. World J Hepatol 2018; 10: 907–910.
Google Scholar | Crossref | Medline8. Margini, C, Dufour, JF. The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment. Liver Int 2016; 36: 317–324.
Google Scholar | Crossref | Medline9. Higashi, T, Friedman, SL, Hoshida, Y. Hepatic stellate cells as key target in liver fibrosis. Adv Drug Deliv Rev 2017; 121: 27–42.
Google Scholar | Crossref | Medline10. Tsuchida, T, Friedman, SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol 2017; 14: 397–411.
Google Scholar | Crossref | Medline11. Barry, AE, Baldeosingh, R, Lamm, R, et al. Hepatic stellate cells and hepatocarcinogenesis. Front Cell Dev Biol 2020; 8: 709.
Google Scholar | Crossref | Medline12. Okabe, K, Yaku, K, Tobe, K, et al. Implications of altered NAD metabolism in metabolic disorders. J Biomed Sci 2019; 26: 34.
Google Scholar | Crossref | Medline13. Elhassan, YS, Philp, AA, Lavery, GG. Targeting NAD+ in metabolic disease: new insights into an old molecule. J Endocr Soc 2017; 1: 816–835.
Google Scholar | Crossref | Medline14. Covarrubias, AJ, Perrone, R, Grozio, A, et al. NAD(+) metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol 2021; 22: 119–141.
Google Scholar | Crossref | Medline15. Rajman, L, Chwalek, K, Sinclair, DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metab 2018; 27: 529–547.
Google Scholar | Crossref | Medline16. Yaku, K, Okabe, K, Nakagawa, T. NAD metabolism: Implications in aging and longevity. Ageing Res Rev 2018; 47: 1–17.
Google Scholar | Crossref | Medline17. Garten, A, Schuster, S, Penke, M, et al. Physiological and pathophysiological roles of NAMPT and NAD metabolism. Nat Rev Endocrinol 2015; 11: 535–546.
Google Scholar | Crossref | Medline | ISI18. Travelli, C, Colombo, G, Mola, S, et al. NAMPT: a pleiotropic modulator of monocytes and macrophages. Pharmacol Res 2018; 135: 25–36.
Google Scholar | Crossref | Medline19. Wang, LF, Wang, XN, Huang, CC, et al. Inhibition of NAMPT aggravates high fat diet-induced hepatic steatosis in mice through regulating Sirt1/AMPKalpha/SREBP1 signaling pathway. Lipids Health Disease 2017; 16: 82.
Google Scholar | Crossref | Medline20. Zhou, CC, Yang, X, Hua, X, et al. Hepatic NAD(+) deficiency as a therapeutic target for non-alcoholic fatty liver disease in ageing. Br J Pharmacol 2016; 173: 2352–2368.
Google Scholar | Crossref | Medline21. Xiong, X, Yu, J, Fan, R, et al. NAMPT overexpression alleviates alcohol-induced hepatic steatosis in mice. PLoS One 2019; 14: e0212523.
Google Scholar | Crossref | Medline22. Zhang, H, Chen, F, Fan, X, et al. Quantitative proteomic analysis on activated hepatic stellate cells reversion reveal STAT1 as a key regulator between liver fibrosis and recovery. Sci Rep 2017; 7: 44910.
Google Scholar | Crossref | Medline23. Mederacke, I, Dapito, DH, Affo, S, et al. High-yield and high-purity isolation of hepatic stellate cells from normal and fibrotic mouse livers. Nat Proto 2015; 10: 305–315.
Google Scholar | Crossref | Medline24. Xu, L, Hui, AY, Albanis, E, et al. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 2005; 54: 142–151.
Google Scholar | Crossref | Medline | ISI25. Shayakhmetov, DM, Li, ZY, Ni, S, et al. Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors. J Virol 2004; 78: 5368–5381.
Google Scholar | Crossref | Medline26. Yoshino, J, Mills, KF, Yoon, MJ, et al. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab 2011; 14: 528–536.
Google Scholar | Crossref | Medline | ISI27. Mitchell, SJ, Bernier, M, Aon, MA, et al. Nicotinamide improves aspects of healthspan, but not lifespan, in mice. Cell Metab 2018; 27: 667–676 e4.
Google Scholar | Crossref | Medline28. Canto, C, Houtkooper, RH, Pirinen, E, et al. The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab 2012; 15: 838–847.
Google Scholar | Crossref | Medline | ISI29. Jiang, R, Zhou, Y, Wang, S, et al. Nicotinamide riboside protects against liver fibrosis induced by CCl4 via regulating the acetylation of Smads signaling pathway. Life Sci 2019; 225: 20–28.
Google Scholar | Crossref | Medline30. Pham, TX, Bae, M, Kim, MB, et al. Nicotinamide riboside, an NAD+ precursor, attenuates the development of liver fibrosis in a diet-induced mouse model of liver fibrosis. Biochim Biophys Acta Mol Basis Dis 2019; 1865(9): 2451–2463.
Google Scholar | Crossref | Medline31. Dong, XC . Sirtuin biology and relevance to diabetes treatment. Diabetes Manag (Lond) 2012; 2: 243–257.
Google Scholar | Crossref32. Li, M, Hong, W, Hao, C, et al. SIRT1 antagonizes liver fibrosis by blocking hepatic stellate cell activation in mice. FASEB J 2018; 32: 500–511.
Google Scholar | Crossref | Medline33. Li, M, Hong, W, Hao, C, et al. Hepatic stellate cell-specific deletion of SIRT1 exacerbates liver fibrosis in mice. Biochim Biophys Acta. 2017; 1863: 3202–3211.
Google Scholar | Crossref34. Wu, Y, Liu, X, Zhou, Q, et al. Silent information regulator 1 (SIRT1) ameliorates liver fibrosis via promoting activated stellate cell apoptosis and reversion. Toxicol Applied Pharmacol 2015; 289: 163–176.
Google Scholar | Crossref | Medline35. Arteaga, M, Shang, N, Ding, X, et al. Inhibition of SIRT2 suppresses hepatic fibrosis. Am J Physiol Gastrointest Liver Physiol 2016; 310: G1155–G1168.
Google Scholar | Crossref | Medline36. Jiang, JX, Chen, X, Serizawa, N, et al. Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4/NOX1 inhibitor in vivo. Free Radic Biol Med 2012; 53: 289–296.
Google Scholar | Crossref | Medline37. Dahl, TB, Haukeland, JW, Yndestad, A, et al. Intracellular nicotinamide phosphoribosyltransferase protects against hepatocyte apoptosis and is down-regulated in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2010; 95: 3039–3047.
Google Scholar | Crossref | Medline